Neoplasma Vol.57, No.1, p.8-14, 2010
|
| Title: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma |
| Author: J. MINARIK, V. SCUDLA, J. BACOVSKY, M. ZEMANOVA, T. PIKA, M. ORDELTOVA, K. LANGOVA |
|
Abstract: We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI ven after 40 months (median overall survival 25 vs 10months, p = 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients.
|
|
| Keywords: myeloma – prognostication – proliferative index – biological therapy |
|
|
|
| Year: 2010, Volume: 57, Issue: 1 |
Page From: 8, Page To: 14 |
doi:10.4149/neo_2010_01_008
|
|
 download file |
|
|
|
|
